コンテンツへスキップ
Merck
すべての画像(1)

Key Documents

安全性情報

308M-1

Sigma-Aldrich

Oct-2 (MRQ-2) Mouse Monoclonal Antibody

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

mouse

品質水準

100
500

結合体

unconjugated

抗体製品の状態

diluted ascites fluid

抗体製品タイプ

primary antibodies

クローン

MRQ-2, monoclonal

詳細

For In Vitro Diagnostic Use in Select Regions (See Chart)

形状

buffered aqueous solution

化学種の反応性

human

包装

vial of 0.1 mL concentrate (308M-14)
vial of 0.5 mL concentrate (308M-15)
bottle of 1.0 mL predilute (308M-17)
vial of 1.0 mL concentrate (308M-16)
bottle of 7.0 mL predilute (308M-18)

メーカー/製品名

Cell Marque

テクニック

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100

アイソタイプ

IgG1κ

コントロール

tonsil

輸送温度

wet ice

保管温度

2-8°C

視覚化

nuclear

遺伝子情報

human ... POU2F2(5452)

詳細

Octamer-binding transcription factor-2 (Oct-2) is a transcription factor of the POU homeo-domain family. It binds to Ig gene octamer sites and plays a crucial role in B-cell development and differentiation, as well as in B-cell identity. Oct-2 is expressed in a subset of normal B-lymphocytes and is expressed in various B-cell lymphomas as well as nodular lymphocyte predominant Hodgkin lymphoma, while it is typically not expressed in the Reed–Sternberg and Hodgkin (RS/H) cells of classical Hodgkin lymphoma.


Oct-2 is a transcription factor of the POU homeo-domain family that binds to the Ig gene octamer sites, regulating B-cell-specific genes. These are involved in proliferation and differentiation and despite the scarce evidence for Oct-2 expression in T cells, it has been shown that this factor participates in transcriptional regulation during T-cell activation. Oct-2 activity is dependent on phosphorylation and alternatitive splicing, although it seems that the level of its expression can be used as a marker of B-cell lineage and differentiation. The following show high levels of Oct-2 expression: germinal center B-cells, mantle B-cells, monocytoid B-cells, and plasma cells. Various lymphomas are also positive for this marker including the following: B-chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, plasmacytoma, Burkitt lymphoma, diffuse large cell lymphoma, diffuse large B-cell lymphoma, T-cell rich B-cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, classic Hodgkin lymphoma.

Several studies of Oct-2 expression have shown a low level expression in pre-B, T-cell, myelomonocytic, and epithelial cell lines, whereas all mature B-cell lines display high levels of expression. Analysis of Oct-2 expression in primary Hodgkin’s lymphoma (HLs) and cell lines derived from it showed that the tumor cells analyzed had high levels of expression and activity, suggesting a common B-cell origin for all types of HLs.

Associated products: bcl-6, CD20, CD79a, PAX-5, BOB.1

品質


IVD

IVD

IVD

RUO

関連事項

Oct-2 Positive Control Slides, Product No. 308S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

物理的形状

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

調製ノート

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

その他情報

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法的情報

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

12 - Non Combustible Liquids

WGK

WGK 2

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

308M-12-VENT:
308M-16:
308M-17:
308M-14:
308M-16-RUO:
308M-15:
308M-12:
308M-15-RUO:
308M-13:
308M-18-RUO:
308M-17-RUO:
308M-14-RUO:
308M-11:
308M-18:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Christian Hallermann et al.
Journal of the American Academy of Dermatology, 56(4), 588-597 (2007-02-10)
There is a growing body of literature that has enhanced our understanding of the biology of primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) including in the context of gene profiling studies. Recent studies have demonstrated an activated proliferation profile associated
Mónica García-Cosío et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 17(12), 1531-1538 (2004-07-17)
Hodgkin's lymphoma can be considered in most cases a B-cell lymphoma due to the presence of potentially functional immunoglobulin (Ig) gene rearrangements in the neoplastic cells. In contrast to lymphocyte-predominant Hodgkin's lymphoma, Hodgkin/Reed-Sternberg (HRS) cells from classical Hodgkin's lymphoma have
Patrick Browne et al.
American journal of clinical pathology, 120(5), 767-777 (2003-11-12)
Even with routine immunohistochemical evaluation, distinguishing classic Hodgkin lymphoma (CHL) from diffuse large B-cell lymphoma (DLBCL) or anaplastic large cell lymphoma (ALCL) can be difficult. In these cases, the transcription factors (B cell-specific activator protein [BSAP], octamer-binding transcription factor 2
Sarah E Gibson et al.
American journal of clinical pathology, 126(6), 916-924 (2006-11-01)
The aberrant expression of the B-cell transcription factor PAX5 has been described in a subset of acute myeloid leukemia (AML) with t(8;21)(q22;q22) in association with B-cell antigen expression. However, the expression of other B cell-associated transcription factors, particularly OCT-2 and

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)